Zura Bio (ZURA) Competitors $4.38 -0.02 (-0.45%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZURA vs. SAVA, PRAX, ANIP, GYRE, CALT, AUTL, BCAX, EVO, TYRA, and COGTShould you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Cassava Sciences (SAVA), Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), Gyre Therapeutics (GYRE), Calliditas Therapeutics AB (publ) (CALT), Autolus Therapeutics (AUTL), Bicara Therapeutics (BCAX), Evotec (EVO), Tyra Biosciences (TYRA), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Zura Bio vs. Cassava Sciences Praxis Precision Medicines ANI Pharmaceuticals Gyre Therapeutics Calliditas Therapeutics AB (publ) Autolus Therapeutics Bicara Therapeutics Evotec Tyra Biosciences Cogent Biosciences Cassava Sciences (NASDAQ:SAVA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher earnings and valuation, SAVA or ZURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.41-18.59Zura BioN/AN/A-$69.24MN/AN/A Is SAVA or ZURA more profitable? Zura Bio's return on equity of -28.83% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.23% -68.31% Zura Bio N/A -28.83%-22.91% Does the MarketBeat Community favor SAVA or ZURA? Cassava Sciences received 82 more outperform votes than Zura Bio when rated by MarketBeat users. However, 88.24% of users gave Zura Bio an outperform vote while only 65.54% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9765.54% Underperform Votes5134.46% Zura BioOutperform Votes1588.24% Underperform Votes211.76% Does the media prefer SAVA or ZURA? In the previous week, Cassava Sciences and Cassava Sciences both had 5 articles in the media. Zura Bio's average media sentiment score of 0.15 beat Cassava Sciences' score of 0.13 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SAVA or ZURA? Cassava Sciences currently has a consensus target price of $111.50, indicating a potential upside of 325.41%. Zura Bio has a consensus target price of $17.33, indicating a potential upside of 295.74%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Zura Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Zura Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals hold more shares of SAVA or ZURA? 38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 9.0% of Cassava Sciences shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, SAVA or ZURA? Cassava Sciences has a beta of -0.63, meaning that its stock price is 163% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. SummaryZura Bio beats Cassava Sciences on 9 of the 12 factors compared between the two stocks. Ad Porter & CompanyTrue paradigm shiftI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Zura Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZURA vs. The Competition Export to ExcelMetricZura BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$295.71M$3.15B$5.33B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E RatioN/A16.44128.4016.13Price / SalesN/A321.081,491.7792.21Price / CashN/A149.0539.5634.18Price / Book2.374.024.765.07Net Income-$69.24M-$42.25M$118.92M$225.46M7 Day Performance-7.59%1.81%-0.39%0.07%1 Month Performance13.77%8.56%6.06%3.93%1 Year Performance-6.81%35.10%38.23%32.51% Zura Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZURAZura Bio2.5793 of 5 stars$4.38-0.5%$17.33+295.7%-6.8%$294.37MN/A0.003SAVACassava Sciences3.7333 of 5 stars$26.55-2.7%$111.50+320.0%+70.3%$1.27BN/A-18.8330Upcoming EarningsNews CoveragePRAXPraxis Precision Medicines2.7039 of 5 stars$71.54+1.5%$143.44+100.5%+375.4%$1.22B$1.77M-6.98110Upcoming EarningsAnalyst ForecastPositive NewsANIPANI Pharmaceuticals4.8477 of 5 stars$58.32-1.6%$77.33+32.6%-5.6%$1.22B$538.95M49.85642Short Interest ↓Gap UpGYREGyre TherapeuticsN/A$14.21+0.9%N/AN/A$1.22B$111.59M0.0040Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AUTLAutolus Therapeutics3.132 of 5 stars$4.44flat$8.70+95.9%+18.6%$1.18B$10.50M-3.83330Short Interest ↓BCAXBicara Therapeutics1.6508 of 5 stars$22.50-0.5%$41.00+82.2%N/A$1.16BN/A0.0032Positive NewsEVOEvotec2.5238 of 5 stars$3.52-3.0%$5.93+68.6%-54.8%$1.16B$845.74M0.005,061Upcoming EarningsTYRATyra Biosciences3.7817 of 5 stars$21.93-23.3%$31.00+41.4%+38.1%$1.15BN/A-12.9820Upcoming EarningsInsider BuyingHigh Trading VolumeCOGTCogent Biosciences2.561 of 5 stars$11.97-0.3%$14.67+22.5%+43.1%$1.14BN/A-4.8380Upcoming Earnings Related Companies and Tools Related Companies SAVA Alternatives PRAX Alternatives ANIP Alternatives GYRE Alternatives CALT Alternatives AUTL Alternatives BCAX Alternatives EVO Alternatives TYRA Alternatives COGT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZURA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZURA Stock Alerts